Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

0.9100 -0.0400 (-4.21%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Positive Results of Alzheimer’s Study
Via Investor Brand Network
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Successfully Completes First Phase of Dose-Ranging SPC-15 Study
Via Investor Brand Network
Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder
Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD).  
Via Benzinga
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy
Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly ad 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Regulatory Approval for Ketamine Implant, Moves Forward with Partner to Next Stage of Development
Via Investor Brand Network
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy 
Via Benzinga
SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan 
Via Benzinga
Topics Cannabis
Exposures Cannabis
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Inks Exclusive License Agreement with Medspray Pharma BV
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder Candidate
Silo Pharma Inc (NASDAQ: SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! 
Via InvestorPlace
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Initiate Dose-Ranging Study, Positioning for Early Start of Phase 1 Clinical Trial of SPC-15
Via Investor Brand Network
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial 
From Silo Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.